CORRIGENDUM

Scior T, Guevara-Garcia JA, Melendez FJ, et al. Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B. *Drug Des Devel Ther*. 2010;4:231–242.

Error in author list

Dr Melendez was incorrectly affiliated in “Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B”, published in *Drug Design, Development and Therapy*. The corrected list of authors and affiliations follows:

Thomas Scior¹, José Antonio Guevara-García², FJ Melendez¹, Hassan H Abdallah³, Quoc-Tuan Do⁴, Philippe Bernard⁴

¹Facultad de Ciencias Químicas, Universidad Autónoma de Puebla, Pue, Puebla, Mexico; ²Faculty of Basic Sciences, Technology and Engineering, Laboratory of Research in Bioinorganic and Bioremediation, Universidad Autónoma de Tlaxcala, Apizaco, Tlaxcala, México; ³School of Chemical Sciences, Universiti Sains Malaysia, Penang, Malaysia;

⁴GreenPharma S.A., 3 Allée du Titane, Orléans, France

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has

also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>